• News
  • Stock Screener
  • Small Caps
  • Guru Portfolios
  • Review
  • News
  • Stock Screener
  • Small Caps
  • Guru Portfolios
  • Review
  • X (Twitter)
  • LinkedIn
Stock Screener·US·Healthcare·RXST
Held by 2 Gurus
Share

RxSight, Inc. Stocks

$ 4.92Last Updated 14.07.2026

Issuer Rating

3/7
Performance

Average

Risk

High

Recommendation

Sell

Market Cap

$ 209.47M

$ 4.92
Key Takeaways

Risk factor

Very high price volatility

Data is available to registered users only
Data is available to registered users only

Profitability factor

Undervalued vs peers

Data is available to registered users only
Data is available to registered users only
Sign up to get free access to key risk and return factors, detailed company valuation, and analyst forecasts
Sign up to access all the key risk and return factors

In Guru Portfolios

Data is available to registered users only
Data is available to registered users only

Portfolio Weight (%)

Data is available to registered users only

Change

Data is available to registered users only

Fund

Data is available to registered users only
Data is available to registered users only
Data is available to registered users only

Portfolio Weight (%)

Data is available to registered users only

Change

Data is available to registered users only

Fund

Data is available to registered users only
Data is available to registered users only
Data is available to registered users only

Portfolio Weight (%)

Data is available to registered users only

Change

Data is available to registered users only

Fund

Data is available to registered users only
Manager
Fund
Portfolio Weight (%)
Change
Data is available to registered users only
Data is available to registered users only
Data is available to registered users only
Data is available to registered users only
Data is available to registered users only
Data is available to registered users only
Data is available to registered users only
Data is available to registered users only
Data is available to registered users only
Data is available to registered users only
Data is available to registered users only
Data is available to registered users only
Sign up, to see portfolios that hold this stock
Sign up, to see portfolios that hold this stock

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

About

As a medical technology enterprise, RxSight, Inc. (which operated as Calhoun Vision, Inc. until its rebranding in February 2017) specializes in the innovation, manufacturing, and distribution of light-adjustable intraocular lenses (LALs). These advanced lenses are specifically designed for use in cataract surgery, serving patients in both domestic and international markets. The cornerstone of the company's offerings is the RxSight system, a sophisticated solution that enables ophthalmologists to precisely tailor and enhance a patient's visual acuity following cataract removal. An integral part of this system is the RxSight light delivery device, an in-office instrument. This device emits UV light in a carefully controlled pattern to modify the LAL, thereby ensuring optimal visual correction after the surgical procedure. RxSight's primary clientele consists of eye surgeons specializing in cataract treatments. The company was founded in 1997 and its corporate headquarters are situated in Aliso Viejo, California.

Company Valuation

Undervalued
6/7

From both historical and forecast perspectives, the stock is underpriced compared to similar stocks.

Data is available to registered users only
Sign up to access detailed valuation

Target Price

Favourable
6/7

The average target price of RXST is 8.95 and suggests 81.9% upside potential. Usually, this means a BUY recommendation among investment firms, or a recommendation to incr

Data is available to registered users only
Sign up to access analyst forecasts

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

Trending

16.07.2026 08:30

United Warned of $6 Billion in Additional Fuel Costs. Why the Profit Forecast Was Raised

16.07.2026 07:30

UBS recommends buying SpaceX shares ahead of a new rocket test. The shares have fallen 33% from their peak.

16.07.2026 03:25

Apple Is on the Hunt for AI Chip Makers — The Information

16.07.2026 02:05

JPMorgan, BlackRock, and Goldman plan to tokenize stocks and government bonds

16.07.2026 01:11

OpenAI has unveiled its first gadget—a keyboard for controlling AI agents

X-channel

Buy

Sell

0 more stocks

Company

  • About
  • Contributors
  • Contacts
  • Legal Information

Social media

  • X (Twitter)
  • LinkedIn

Services

  • Stock Screener
  • Guru Portfolios
  • X (Twitter)
  • LinkedIn
Oninvest© 2026